Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results

Gener-Ricos, Georgina; Haddad, Fadi G.; Sasaki, Koji; Issa, Ghayas C.; Skinner, Jeffrey; Masarova, Lucia; Borthakur, Gautam; Alvarado, Yesid; Garcia-Manero, Guillermo; Jabbour, Elias; Kantarjian, Hagop

doi:10.1016/j.clml.2023.05.009

Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results

Background Dasatinib is a BCR::ABL1 tyrosine kinase inhibitor approved as frontline therapy at a 100 mg daily for chronic myeloid leukemia in chronic phase (CML-CP). The use of a lower dose of dasatinib (50 mg daily) has demonstrated better tolerance and improved outcomes compared with the standa…